Fast evolution of SARS-CoV-2 BA.2.86 to JN.1 under heavy immune pressure

doi:10.1016/S1473-3099(23)00744-2

. 2024 Feb;24(2):e70-e72.

doi: 10.1016/S1473-3099(23)00744-2. Epub 2023 Dec 15.

Fast evolution of SARS-CoV-2 BA.2.86 to JN.1 under heavy immune pressure

Sijie Yang¹, Yuanling Yu², Yanli Xu³, Fanchong Jian⁴, Weiliang Song⁵, Ayijiang Yisimayi⁵, Peng Wang², Jing Wang², Jingyi Liu⁶, Lingling Yu², Xiao Niu⁵, Jing Wang⁵, Yao Wang², Fei Shao², Ronghua Jin³, Youchun Wang⁷, Yunlong Cao⁸

Affiliations

¹ Biomedical Pioneering Innovation Center (BIOPIC), Peking University, Beijing 100871, China; Changping Laboratory, Beijing, China; Peking-Tsinghua Center for Life Sciences, Tsinghua University, Beijing, China.
² Changping Laboratory, Beijing, China.
³ Beijing Ditan Hospital, Capital Medical University, Beijing, China.
⁴ Biomedical Pioneering Innovation Center (BIOPIC), Peking University, Beijing 100871, China; College of Chemistry and Molecular Engineering, Peking University, Beijing 100871, China; Changping Laboratory, Beijing, China.
⁵ Biomedical Pioneering Innovation Center (BIOPIC), Peking University, Beijing 100871, China; School of Life Sciences, Peking University, Beijing 100871, China; Changping Laboratory, Beijing, China.
⁶ Biomedical Pioneering Innovation Center (BIOPIC), Peking University, Beijing 100871, China; College of Future Technology, Peking University, Beijing 100871, China; Changping Laboratory, Beijing, China.
⁷ Changping Laboratory, Beijing, China; Institute of Medical Biology, Chinese Academy of Medical Science and Peking Union Medical College, Kunming, China.
⁸ Biomedical Pioneering Innovation Center (BIOPIC), Peking University, Beijing 100871, China; School of Life Sciences, Peking University, Beijing 100871, China; Changping Laboratory, Beijing, China. Electronic address: yunlongcao@pku.edu.cn.

PMID: 38109919
DOI: 10.1016/S1473-3099(23)00744-2

Fast evolution of SARS-CoV-2 BA.2.86 to JN.1 under heavy immune pressure

Sijie Yang et al. Lancet Infect Dis. 2024 Feb.

. 2024 Feb;24(2):e70-e72.

doi: 10.1016/S1473-3099(23)00744-2. Epub 2023 Dec 15.

Authors

Affiliations

¹ Biomedical Pioneering Innovation Center (BIOPIC), Peking University, Beijing 100871, China; Changping Laboratory, Beijing, China; Peking-Tsinghua Center for Life Sciences, Tsinghua University, Beijing, China.
² Changping Laboratory, Beijing, China.
³ Beijing Ditan Hospital, Capital Medical University, Beijing, China.
⁴ Biomedical Pioneering Innovation Center (BIOPIC), Peking University, Beijing 100871, China; College of Chemistry and Molecular Engineering, Peking University, Beijing 100871, China; Changping Laboratory, Beijing, China.
⁵ Biomedical Pioneering Innovation Center (BIOPIC), Peking University, Beijing 100871, China; School of Life Sciences, Peking University, Beijing 100871, China; Changping Laboratory, Beijing, China.
⁶ Biomedical Pioneering Innovation Center (BIOPIC), Peking University, Beijing 100871, China; College of Future Technology, Peking University, Beijing 100871, China; Changping Laboratory, Beijing, China.
⁷ Changping Laboratory, Beijing, China; Institute of Medical Biology, Chinese Academy of Medical Science and Peking Union Medical College, Kunming, China.
⁸ Biomedical Pioneering Innovation Center (BIOPIC), Peking University, Beijing 100871, China; School of Life Sciences, Peking University, Beijing 100871, China; Changping Laboratory, Beijing, China. Electronic address: yunlongcao@pku.edu.cn.

PMID: 38109919
DOI: 10.1016/S1473-3099(23)00744-2

Erratum in

Correction to Lancet Infect Dis 2023; published online Dec 15. https://doi.org/10.1016/S1473-3099(23)00744-2.
[No authors listed] [No authors listed] Lancet Infect Dis. 2024 Mar;24(3):e156. doi: 10.1016/S1473-3099(23)00822-8. Epub 2024 Jan 3. Lancet Infect Dis. 2024. PMID: 38184002 No abstract available.

No abstract available

PubMed Disclaimer

Conflict of interest statement

YC is the inventor of the provisional patent applications for BD series antibodies, which includes BD55–5514 (SA55). YC is the founder of Singlomics Biopharmaceuticals. All other authors declare no competing interests.

Cited by

Temperature-dependent Spike-ACE2 interaction of Omicron subvariants is associated with viral transmission.
Benlarbi M, Ding S, Bélanger É, Tauzin A, Poujol R, Medjahed H, El Ferri O, Bo Y, Bourassa C, Hussin J, Fafard J, Pazgier M, Levade I, Abrams C, Côté M, Finzi A. Benlarbi M, et al. mBio. 2024 Aug 14;15(8):e0090724. doi: 10.1128/mbio.00907-24. Epub 2024 Jul 2. mBio. 2024. PMID: 38953636 Free PMC article.
Cross-neutralizing antibody against emerging Omicron subvariants of SARS-CoV-2 in infection-naïve individuals with homologous BNT162b2 or BNT162b2(WT + BA.4/5) bivalent booster vaccination.
Cheng SMS, Mok CKP, Li JKC, Chan KKP, Luk KS, Lee BHW, Gu H, Chan KCK, Tsang LCH, Yiu KYS, Ling KKC, Tang YS, Luk LLH, Yu JKM, Pekosz A, Webby RJ, Cowling BJ, Hui DSC, Peiris M. Cheng SMS, et al. Virol J. 2024 Mar 21;21(1):70. doi: 10.1186/s12985-024-02335-9. Virol J. 2024. PMID: 38515117 Free PMC article.
Appearance and Prevalence of JN.1 SARS-CoV-2 Variant in India and Its Clinical Profile in the State of Maharashtra.
Karyakarte RP, Das R, Rajmane MV, Dudhate S, Agarasen J, Pillai P, Chandankhede PM, Labhshetwar RS, Gadiyal Y, Kulkarni PP, Nizarudeen S, Yanamandra S, Taji N, Joshi S, Potdar V. Karyakarte RP, et al. Cureus. 2024 Mar 22;16(3):e56718. doi: 10.7759/cureus.56718. eCollection 2024 Mar. Cureus. 2024. PMID: 38646375 Free PMC article.
Evolving antibody response to SARS-CoV-2 antigenic shift from XBB to JN.1.
Jian F, Wang J, Yisimayi A, Song W, Xu Y, Chen X, Niu X, Yang S, Yu Y, Wang P, Sun H, Yu L, Wang J, Wang Y, An R, Wang W, Ma M, Xiao T, Gu Q, Shao F, Wang Y, Shen Z, Jin R, Cao Y. Jian F, et al. Nature. 2025 Jan;637(8047):921-929. doi: 10.1038/s41586-024-08315-x. Epub 2024 Nov 7. Nature. 2025. PMID: 39510125 Free PMC article.
Bispecific antibodies with broad neutralization potency against SARS-CoV-2 variants of concern.
Rubio AA, Baharani VA, Dadonaite B, Parada M, Abernathy ME, Wang Z, Lee YE, Eso MR, Phung J, Ramos I, Chen T, Nesr GE, Bloom JD, Bieniasz PD, Nussenzweig MC, Barnes CO. Rubio AA, et al. bioRxiv [Preprint]. 2024 May 6:2024.05.05.592584. doi: 10.1101/2024.05.05.592584. bioRxiv. 2024. PMID: 38766244 Free PMC article. Preprint.

See all "Cited by" articles

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science
Other Literature Sources
- The Lens - Patent Citations Database
Medical
- MedlinePlus Health Information
Miscellaneous
- NCI CPTAC Assay Portal

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Fast evolution of SARS-CoV-2 BA.2.86 to JN.1 under heavy immune pressure

Affiliations

Fast evolution of SARS-CoV-2 BA.2.86 to JN.1 under heavy immune pressure

Authors

Affiliations

Erratum in

Conflict of interest statement

Similar articles

Cited by

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical

Miscellaneous